EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Structure‐Activity Relationships, Tolerability and Efficacy of Microtubule‐Active 1,2,4‐Triazolo[1,5‐ a ]pyrimidines as Potential Candidates to Treat Human African Trypanosomiasis**

Ludovica Monti, Lawrence J Liu, Carmine Varricchio, Bobby Lucero, Thibault Alle, Wenqian Yang, Ido Ben-Shalom, Michael Gilson, Kurt R Brunden, Andrea Brancale, Conor R Caffrey, Carlo Ballatore iD

ChemMedChem · 2023

DOI: 10.1002/cmdc.202300193 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2023. Verfasst von Ludovica Monti und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Discovery and Innovation in Parasitic Diseases (CDIPD), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, S…. Hauptthemen laut MEDLINE: Trypanosomiasis, African, Trypanosoma brucei brucei, Trypanocidal Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tubulin and microtubules (MTs) are potential protein targets to treat parasitic infections and our previous studies have shown that the triazolopyrimidine (TPD) class of MT‐active compounds hold promise as antitrypanosomal agents. MT‐targeting TPDs include structurally related but functionally diverse congeners that interact with mammalian tubulin at either one or two distinct interfacial binding sites; namely, the seventh and vinca sites, which are found within or between α,β‐tubulin heterodimers, respectively. Evaluation of the activity of 123 TPD congeners against cultured Trypanosoma brucei enabled a robust quantitative structure‐activity relationship (QSAR) model and the prioritization of two congeners for in vivo pharmacokinetics (PK), tolerability and efficacy studies. Treatment of T. brucei ‐infected mice with tolerable doses of TPDs significantly decreased blood parasitemia within 24 h. Further, two once‐weekly doses at 10 mg/kg of a candidate TPD significantly extended the survival of infected mice relative to infected animals treated with vehicle. Further optimization of dosing and/or the dosing schedule of these CNS‐active TPDs may provide alternative treatments for human African trypanosomiasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Trypanosomiasis, AfricanTrypanosoma brucei bruceiTrypanocidal AgentsHumansMiceAnimalsTubulinPyrimidinesMicrotubulesStructure-Activity RelationshipMammals

Stichwörter der Autor:innen

TriazolopyrimidinesTrypanosoma bruceidrug discoveryhuman African trypanosomiasismicrotubules

Substanzen

TubulinPyrimidinesTrypanocidal Agents

Autor:innen und Institutionen

  • Center for Discovery and Innovation in Parasitic Diseases (CDIPD), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, 92093, La Jolla, CA, USA.
  • Present affiliation: Chemistry Department, Molecular Sciences Research Hub, Imperial College London, 82 Wood Lane, W12 0BZ, London, UK.
  • Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, CF103NB, Cardiff, UK.
  • Department of Chemistry & Biochemistry, University of California, San Diego, 9500 Gilman Drive, 92093, La Jolla, CA, USA.
  • Center for Neurodegenerative Disease Research, Perelman School of Medicine, University of Pennsylvania, 3600 Spruce Street, 19104-6323, Philadelphia, PA, USA.
  • Present affiliation: Vysoká škola chemicko-technologická v Praze, Department of Organic Chemistry, Technická 5, 16628, Prague 6, Czech Republic.

ORCID-Profile: Carlo Ballatore

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Monti, L., Liu, L. J., Varricchio, C., Lucero, B., Alle, T., Yang, W., Ben-Shalom, I., Gilson, M., Brunden, K. R., Brancale, A., Caffrey, C. R., & Ballatore, C. (2023). Structure‐Activity Relationships, Tolerability and Efficacy of Microtubule‐Active 1,2,4‐Triazolo[1,5‐ a ]pyrimidines as Potential Candidates to Treat Human African Trypanosomiasis**. ChemMedChem. https://doi.org/10.1002/cmdc.202300193

Vancouver

Monti L, Liu LJ, Varricchio C, Lucero B, Alle T, Yang W, et al. Structure‐Activity Relationships, Tolerability and Efficacy of Microtubule‐Active 1,2,4‐Triazolo[1,5‐ a ]pyrimidines as Potential Candidates to Treat Human African Trypanosomiasis**. ChemMedChem. 2023. doi:10.1002/cmdc.202300193

BibTeX
@article{Monti2023,
  author = {Monti, Ludovica and Liu, Lawrence J and Varricchio, Carmine and Lucero, Bobby and Alle, Thibault and Yang, Wenqian and Ben-Shalom, Ido and Gilson, Michael and Brunden, Kurt R and Brancale, Andrea and Caffrey, Conor R and Ballatore, Carlo},
  title = {Structure‐Activity Relationships, Tolerability and Efficacy of Microtubule‐Active 1,2,4‐Triazolo[1,5‐ a ]pyrimidines as Potential Candidates to Treat Human African Trypanosomiasis**},
  journal = {ChemMedChem},
  year = {2023},
  doi = {10.1002/cmdc.202300193}
}
Kostenlos starten →